晚期糖基化终末产物受体与肺动脉高压的研究进展

Research Progress of Advanced Glycation End Product Receptor and Pulmonary Hypertension

肺动脉高压(PH)是一种复杂的进行性破坏性心肺血管疾病,具有高致残率和致死率的特点,目前其发病机制尚未明确,而特异性治疗药物昂贵且无法逆转血管重塑。晚期糖基化终末产物受体(RAGE)是细胞膜上具有多种配体的免疫球蛋白超家族成员,可介导多种肺部疾病。RAGE在不同类型PH中均高表达,不同配体与RAGE结合后通过多种机制介导PH,可溶性RAGE(sRAGE)即可竞争性结合配体,未来sRAGE与其他靶向RAGE的治疗方式或可成为PH治疗的新策略。

Pulmonary hypertension(PH)is a complex progressive and destructive cardiopulmonary vascular disease with high morbidity and mortality,with unclear pathogenesis.Specific therapeutic agents are expensive and cannot reverse vascular remodeling.The advanced glycation end product receptor(RAGE),a member of the immunoglobulin superfamily on the cell membrane with multiple ligands,can mediate a variety of lung diseases.High expression of RAGE has been found in different types of PH,and a variety of ligands bind to RAGE and then mediate PH through various mechanisms.The soluble RAGE(sRAGE),binds ligands competitively and may be a new strategy for PH treatment with other therapeutic modalities targeting RAGE.